TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Surgeons Operating On Patient

TAVR reinterventions: What new data tell us about redo, explant trends over time

TAVR reintervention rates remain low. However, they are slowly rising as the procedure is used more to treat patients with severe aortic stenosis. Researchers think this trend may continue going forward.

Thumbnail

Stroke risk much higher for TAVR patients with carotid artery stenosis

Screening TAVR patients for CAS may provide significant value, according to a new meta-analysis of 15 different studies.

Medtronic Evolut FX+ TAVR

World’s most populous country gains access to Medtronic’s newest TAVR valve

Medtronic developed the self-expanding Evolut FX+ TAVR system with improved coronary access in mind. The FDA-approved device has now officially launched in India. 

The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

TAVR still a safe option for patients with nickel allergies

More research is still needed, as this study only included data from a small number of patients, but TAVR was not linked to any severe adverse events or allergic reactions.

Toby Rogers, MD, PhD, associate professor of medicine Georgetown University, and interventional cardiologist at MedStar Heart and Vascular Institute Structural Heart Disease program, explains how the transcatheter electrosurgical procedures for transcaval access, SESAME, LAMPOON and BASILICA has helped large numbers of patients receive transcatheter heart valves who otherwise would have been disqualified due to anatomical issues.

Advances in electrosurgical techniques have helped thousands of transcatheter valve patients

Toby Rogers, MD, associate professor of medicine at Georgetown University and an interventional cardiologist at MedStar, explains how electrosurgical procedures for transcaval access have helped large numbers of patients receive transcatheter heart valves who otherwise would have been disqualified due to anatomical issues. 
 

Thumbnail

No sedation required: Local anesthesia enough for most TAVR patients

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

Abbott's Navitor TAVR valve

Abbott receives expanded approval for Navitor TAVR system

Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.

Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

Medtronic receives updated FDA approval for redo TAVR

The company also launched a new clinical trial designed to follow redo TAVR patients who present with symptomatic bioprosthetic valve failure for up to five years.

Displaying 73 - 80 of 597
Design by Adaptive Theme